122 related articles for article (PubMed ID: 26750488)
1. Upregulation and axonal transport of synaptotagmin-IV in the direct-pathway medium spiny neurons in hemi-parkinsonian rats induced by dopamine D1 receptor stimulation.
Tratnjek L; Glavan G; Višnjar T; Živin M
Eur J Neurosci; 2016 Apr; 43(7):885-98. PubMed ID: 26750488
[TBL] [Abstract][Full Text] [Related]
2. Differential expression of striatal synaptotagmin mRNA isoforms in hemiparkinsonian rats.
Glavan G; Zivin M
Neuroscience; 2005; 135(2):545-54. PubMed ID: 16111820
[TBL] [Abstract][Full Text] [Related]
3. Dopaminergic regulation of synaptotagmin I and IV mRNAs in hemiparkinsonian rats.
Glavan G; Zorec R; Babic K; Sket D; Zivin M
Neuroreport; 2000 Dec; 11(18):4043-7. PubMed ID: 11192626
[TBL] [Abstract][Full Text] [Related]
4. Failure of MK-801 to suppress D1 receptor-mediated induction of locomotor activity and striatal preprotachykinin mRNA expression in the dopamine-depleted rat.
Campbell BM; Kreipke CW; Walker PD
Neuroscience; 2006; 137(2):505-17. PubMed ID: 16289829
[TBL] [Abstract][Full Text] [Related]
5. The full D1 dopamine receptor agonist SKF-82958 induces neuropeptide mRNA in the normosensitive striatum of rats: regulation of D1/D2 interactions by muscarinic receptors.
Wang JQ; McGinty JF
J Pharmacol Exp Ther; 1997 May; 281(2):972-82. PubMed ID: 9152408
[TBL] [Abstract][Full Text] [Related]
6. Effect of apomorphine on striatal synaptotagmin 7 mRNA levels in reserpinized rats.
Pal R; Zivin M; Milutinovic A; Jernej B; Glavan G
Neurosci Lett; 2007 Sep; 424(3):194-8. PubMed ID: 17719177
[TBL] [Abstract][Full Text] [Related]
7. Striatal D1 medium spiny neuron activation induces dyskinesias in parkinsonian mice.
Perez XA; Zhang D; Bordia T; Quik M
Mov Disord; 2017 Apr; 32(4):538-548. PubMed ID: 28256010
[TBL] [Abstract][Full Text] [Related]
8. Intermittent L-DOPA treatment differentially alters synaptotagmin 4 and 7 gene expression in the striatum of hemiparkinsonian rats.
Glavan G
Brain Res; 2008 Oct; 1236():216-24. PubMed ID: 18721798
[TBL] [Abstract][Full Text] [Related]
9. Dopaminergic treatment weakens medium spiny neuron collateral inhibition in the parkinsonian striatum.
Wei W; Ding S; Zhou FM
J Neurophysiol; 2017 Mar; 117(3):987-999. PubMed ID: 27927785
[TBL] [Abstract][Full Text] [Related]
10. Stronger Dopamine D1 Receptor-Mediated Neurotransmission in Dyskinesia.
Farré D; Muñoz A; Moreno E; Reyes-Resina I; Canet-Pons J; Dopeso-Reyes IG; Rico AJ; Lluís C; Mallol J; Navarro G; Canela EI; Cortés A; Labandeira-García JL; Casadó V; Lanciego JL; Franco R
Mol Neurobiol; 2015 Dec; 52(3):1408-1420. PubMed ID: 25344317
[TBL] [Abstract][Full Text] [Related]
11. MK-801 alters the effects of priming with L-DOPA on dopamine D1 receptor-induced changes in neuropeptide mRNA levels in the rat striatal output neurons.
Van De Witte SV; Groenewegen HJ; Voorn P
Synapse; 2002 Jan; 43(1):1-11. PubMed ID: 11746728
[TBL] [Abstract][Full Text] [Related]
12. Priming of 6-hydroxydopamine-lesioned rats with L-DOPA or quinpirole results in an increase in dopamine D1 receptor-dependent cyclic AMP production in striatal tissue.
Pinna A; Morelli M; Drukarch B; Stoof JC
Eur J Pharmacol; 1997 Jul; 331(1):23-6. PubMed ID: 9274925
[TBL] [Abstract][Full Text] [Related]
13. Interactions of D1 and D2 dopamine receptors on the ipsilateral vs. contralateral side in rats with unilateral lesions of the dopaminergic nigrostriatal pathway.
Sonsalla PK; Manzino L; Heikkila RE
J Pharmacol Exp Ther; 1988 Oct; 247(1):180-5. PubMed ID: 2971797
[TBL] [Abstract][Full Text] [Related]
14. Modulation of neuroleptic activity of 9,10-didehydro-N-methyl-(2-propynyl)-6-methyl-8-aminomethylergoline bimaleinate (LEK-8829) by D1 intrinsic activity in hemi-parkinsonian rats.
Glavan G; Sket D; Zivin M
Mol Pharmacol; 2002 Feb; 61(2):360-8. PubMed ID: 11809861
[TBL] [Abstract][Full Text] [Related]
15. Repeated D1 dopamine receptor agonist administration prevents the development of both D1 and D2 striatal receptor supersensitivity following denervation.
Hu XT; White FJ
Synapse; 1992 Mar; 10(3):206-16. PubMed ID: 1532677
[TBL] [Abstract][Full Text] [Related]
16. Dopamine supersensitivity and D1/D2 synergism are unrelated to changes in striatal receptor density.
LaHoste GJ; Marshall JF
Synapse; 1992 Sep; 12(1):14-26. PubMed ID: 1357762
[TBL] [Abstract][Full Text] [Related]
17. Loss of glutamic acid decarboxylase (Gad67) in striatal neurons expressing the Drdr1a dopamine receptor prevents L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned mice.
Zhang K; Chammas C; Soghomonian JJ
Neuroscience; 2015 Sep; 303():586-94. PubMed ID: 26188284
[TBL] [Abstract][Full Text] [Related]
18. N-methyl-D-aspartate receptor blockade attenuates D1 dopamine receptor modulation of neuronal activity in rat substantia nigra.
Huang KX; Bergstrom DA; Ruskin DN; Walters JR
Synapse; 1998 Sep; 30(1):18-29. PubMed ID: 9704877
[TBL] [Abstract][Full Text] [Related]
19. Levodopa induces a cytoplasmic localization of D1 dopamine receptors in striatal neurons in Parkinson's disease.
Muriel MP; Bernard V; Levey AI; Laribi O; Abrous DN; Agid Y; Bloch B; Hirsch EC
Ann Neurol; 1999 Jul; 46(1):103-11. PubMed ID: 10401786
[TBL] [Abstract][Full Text] [Related]
20. L-DOPA treatment selectively restores spine density in dopamine receptor D2-expressing projection neurons in dyskinetic mice.
Suárez LM; Solís O; Caramés JM; Taravini IR; Solís JM; Murer MG; Moratalla R
Biol Psychiatry; 2014 May; 75(9):711-22. PubMed ID: 23769604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
